



**HARVARD BIOSCIENCE, INC. THIRD AMENDED AND RESTATED 2000**

**STOCK OPTION AND INCENTIVE PLAN**

**(Full Title of the Plan)**

**Jeffrey A. Duchemin, Chief Executive Officer**

**HARVARD BIOSCIENCE, INC.**

**84 October Hill Road**

**Holliston, Massachusetts 01746**

**(508) 893-8999**

**(Name, address, and telephone number, including area code, of agent for service)**

*With copies to:*

**Chad J. Porter**

**Burns & Levinson LLP**

**125 Summer Street**

**Boston, Massachusetts 02110**

**(617) 345-3000**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

(Do not check if a smaller reporting company) Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act

**Calculation of Registration Fee**

<b>Title of Securities to be Registered</b>	<b>Amount to be Registered(1)(2)</b>	<b>Proposed Maximum Offering Price Per Share(3)</b>	<b>Proposed Maximum Aggregate Offering Price(3)</b>	<b>Amount of Registration Fee</b>
Common Stock, par value \$0.01 per share	3,400,000 shares	\$4.30	\$14,620,000	\$1,821

This Registration Statement relates to 3,400,000 shares of Common Stock, par value \$0.01 per share, of Harvard Bioscience, Inc. (“Common Stock”) available for issuance under the Harvard Bioscience, Inc. Third Amended and (1) Restated 2000 Stock Option and Incentive Plan (together with previous versions of such plan, the “Plan”); plus such indeterminate number of additional shares of Common Stock as may be required pursuant to the Plan in the event of a stock dividend, stock split, split-up, recapitalization or other similar event.

The Company previously filed a Registration Statement on Form S-8 on January 17, 2001 (SEC File No. 333-53848), registering the issuance of 4,849,096 shares of Common Stock under the Plan and other equity plans of the Company, as amended by Post-Effective Amendment No.1 to Form S-8 filed on June 15, 2001 registering the issuance of an additional 263,202 shares of Common Stock under the Plan. On April 15, 2003, the Company filed a Registration Statement on Form S-8 (SEC File No. 333-104544) registering the issuance of 787,413 additional shares of Common Stock under the Plan. On June 28, 2006, the Company filed a Registration Statement on Form S-8 (SEC File No. 333-135418) registering the issuance of 2,067,060 additional shares of (2) Common Stock under the Plan. On May 19, 2008, the Company filed a Registration Statement on Form S-8 (SEC File No. 333-151003) registering the issuance of 2,500,000 additional shares of Common Stock under the Plan. On May 25, 2011, the Company filed a Registration Statement on Form S-8 (SEC File No. 333-174476) registering the issuance of 3,700,000 additional shares of Common Stock under the Plan. On June 5, 2015, the Company filed a Registration Statement on Form S-8 (SEC File No. 333-204760) registering the issuance of 2,500,000 additional shares of Common Stock under the Plan. By filing this Registration Statement in accordance with Instruction E to Form S-8, the Company registers the issuance of the 3,400,000 additional shares of Common Stock approved for issuance under the Plan at the Annual Meeting of Stockholders of the Company held on May 17, 2018.

This estimate is made pursuant to Rule 457(c) and (h) under the Securities Act of 1933, as amended (the “Securities Act”), solely for the purpose of determining the amount of the registration fee. The registration fee is based upon the (3) average of the high and low sales prices for a share of Common Stock on May 29, 2018, as reported on the NASDAQ Global Market.

The Company previously filed (i) a Registration Statement on Form S-8 with the Securities and Exchange Commission, or SEC, on January 17, 2001 as amended on June 15, 2001 (SEC File No. 333-53848), (ii) a Registration Statement on Form S-8 with the SEC on April 15, 2003 (SEC File No. 333-104544), (iii) a Registration Statement on Form S-8 with the SEC on June 28, 2006 (SEC File No. 333-135418) (iv) a Registration Statement on Form S-8 with the SEC on May 19, 2008 (SEC File No. 333-151003), (v) a Registration Statement on Form S-8 with the SEC on May 25, 2011 (SEC File No. 333-174476) and (vi) a Registration Statement on Form S-8 with the SEC on June 5, 2015 (SEC File No. 333-204760) (each filed to register shares to be issued pursuant to the Plan (collectively, the “Original Filings”). This Registration Statement registers additional shares of the Company’s Common Stock to be issued pursuant to the Plan. The contents of the Original Filings are incorporated by reference into this Registration Statement pursuant to General Instruction E of Form S-8.

## **PART II**

### **INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

#### **Item 3. Incorporation of Documents by Reference.**

The Registrant is subject to the informational and reporting requirements of Sections 13(a), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and in accordance therewith files reports, proxy statements and other information with the Commission. The following documents, which are on file with the Commission, are incorporated in this registration statement by reference:

- (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Commission on March 16, 2018;
- (b) All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act, since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K described in (a) above; and
- (c) The description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A (File No. 000-31923) filed with the Commission on November 9, 2000 under the Exchange Act, including any amendment or report filed for the purpose of updating such description.

All documents subsequently filed by the registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of the filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

### **Item 8. Exhibits**

The Exhibit Index immediately preceding the exhibits is incorporated herein by reference.

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Holliston, Massachusetts, on this 1st day of June, 2018.

HARVARD BIOSCIENCE, INC.

By: /s/ Jeffrey A. Duchemin  
Jeffrey A. Duchemin, *Chief Executive Officer*

## POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS that each individual whose signature appears below constitutes and appoints each of Jeffrey A. Duchemin and Robert E. Gagnon as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any registration statement for the same offering that is to be effective upon filing pursuant to Rule 462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated. Each person listed below has signed this registration statement as an officer or director of Harvard Bioscience, Inc.

<b>Signature</b>	<b>Title</b>	<b>Date</b>
/s/ Jeffrey A. Duchemin	Director and Chief Executive Officer	June 1, 2018

Edgar Filing: HARVARD BIOSCIENCE INC - Form S-8

Jeffrey A. Duchemin	(Principal Executive Officer)	
/s/ Robert E. Gagnon	Chief Financial Officer	June 1, 2018
Robert E. Gagnon	(Principal Financial Officer and Principal Accounting Officer)	
/s/ Katherine Eade	Director	June 1, 2018
Katherine Eade		
/s/ James Green	Director	June 1, 2018
James Green		
/s/ John F. Kennedy	Director	June 1, 2018
John F. Kennedy		
/s/ Thomas Loewald	Director	June 1, 2018
Thomas Loewald		
/s/ Bertrand Loy	Director	June 1, 2018
Bertrand Loy		



**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
<u>4.1(1)</u>	Second Amended and Restated Certificate of Incorporation of Harvard Bioscience, Inc.
<u>4.2(1)</u>	Amended and Restated Bylaws of Harvard Bioscience, Inc.
<u>4.3(2)</u>	Amendment No. 1 to Amended and Restated Bylaws of Harvard Bioscience, Inc.
<u>4.4(1)</u>	Specimen certificate for shares of Common Stock, \$0.01 par value, of Harvard Bioscience, Inc.
<u>4.5(3)</u>	Amended and Restated Securityholders' Agreement dated as of March 2, 1999 by and among Harvard Apparatus, Inc., Pioneer Partnership II, Pioneer Capital Corp., First New England Capital, L.P. and Citizens Capital, Inc. and Chane Graziano and David Green
<u>4.6(4)</u>	Harvard Bioscience, Inc. Third Amended and Restated 2000 Stock Option and Incentive Plan, as amended
<u>*5.1</u>	Legal opinion from Burns & Levinson LLP
<u>*23.1</u>	Consent of Grant Thornton LLP
<u>*23.2</u>	Consent of KPMG LLP
<u>*23.3</u>	Consent of RSM US LLP
<u>23.4</u>	Consent of Burns & Levinson LLP (contained in the opinion filed as Exhibit 5.1 to this Registration Statement)
<u>24.1</u>	Power of attorney (included on the signature page to this Registration Statement)

\* Filed herewith.

- (1) Previously filed as an exhibit to the Company's Registration Statement on Form S-1/A (File No. 333-45996) (filed on November 9, 2000) and incorporated by reference thereto.
- (2) Previously filed as an exhibit to the Company's Current Report on Form 8-K (filed on November 1, 2007) and incorporated by reference thereto.
- (3) Previously filed as an exhibit to the Company's Registration Statement on Form S-1/A (File No. 333-45996) (filed on October 25, 2000) and incorporated by reference thereto.
- (4) Previously filed as Appendix A to the Company's Definitive Schedule 14A (Proxy Statement) (filed on April 6, 2018) and incorporated by reference thereto.

